Stockscreener 앱 받기
3.785
2.85%
0.105
시장 영업 전:
3.94
0.155
+4.10%
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00 - Defense World
What makes Prime Medicine Inc. stock price move sharplyHigh Return Trade Roadmap with Setup Filters - Newser
Prime Medicine Inc. stock trendline breakdownFree Consistent Income Focused Trade List - Newser
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
How high can Prime Medicine Inc. stock goFree Community Verified Stock Suggestions - Newser
Prime Medicine stock price target lowered to $10 at Chardan on cash update - Investing.com Canada
Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position - TipRanks
Prime Medicine Inc. stock retracement – recovery analysisFree Stock Market Entry Timing Signals - Newser
Prime Medicine Reports Q2 2025 Results and Strategic Updates - TipRanks
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
PRME Revenue Misses by 73% - The Motley Fool
Prime Medicine reports Q2 EPS (41c), consensus (34c) - TipRanks
Prime Medicine, Inc. SEC 10-Q Report - TradingView
Prime Medicine, Inc. Q2 operating expenses USD 54.492 million - MarketScreener
Prime Medicine Achieves Breakthrough in Gene Editing Trial, Raises $168M to Advance Genetic Disease Cures - Stock Titan
Alphabet Discloses $4.95 Million Equity Purchase in Prime Medicine via GV - TechGraph
Major Investment Alert: Prime Medicine, Inc. Sees Significant Share Purchase! - TipRanks
Prime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying Activity - Defense World
Why Prime Medicine Inc. stock attracts strong analyst attentionPrice Action Summary and Entry Strategy Guide - Newser
Prime Medicine Holds Special Stockholder Meeting - TipRanks
Bank of New York Mellon Corp Acquires 26,478 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI) - Defense World
Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity - Defense World
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering - Wilson Sonsini
Prime Medicine Surges 8.5% Amid KDJ Golden Cross Signal and Biotech Sector Rally - AInvest
Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Driving the Move? - AInvest
Why is Prime Medicine Inc. stock attracting strong analyst attentionAchieve rapid capital gains with smart investing - Jammu Links News
What are the latest earnings results for Prime Medicine Inc.Free Consultation - Jammu Links News
What institutional investors are buying Prime Medicine Inc. stockGet insider insights into market trends - Jammu Links News
What drives Prime Medicine Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What are Prime Medicine Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News
When is Prime Medicine Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - Jammu Links News
What analysts say about Prime Medicine Inc. stockStay informed with daily expert analysis - Jammu Links News
Is Prime Medicine Inc. a growth stock or a value stockInvest confidently with advanced analysis tools - Jammu Links News
What is the risk reward ratio of investing in Prime Medicine Inc. stockUnlock powerful market trend analysis - Jammu Links News
Is Prime Medicine Inc. stock overvalued or undervaluedInvest smarter with daily market updates - Jammu Links News
Major Stakeholders Make Bold Moves in Prime Medicine Stock! - TipRanks
Arch venture fund XII buys Prime Medicine shares worth $9.99m - Investing.com Nigeria
Arch venture fund XII buys Prime Medicine shares worth $9.99m By Investing.com - Investing.com South Africa
Prime Medicine shares rise 1.98% after-hours following the closing of a $144.2 million stock offering. - AInvest
Prime Medicine's $144.2M Equity Raise and Strategic Implications - AInvest
Prime Medicine Closes $144.2 Million Stock Offering - MarketScreener
Prime Medicine's Strategic Capital Raise: A Catalyst for Gene Editing Innovation and Shareholder Value - AInvest
Prime Medicine Announces Closing of Public Offering and - GlobeNewswire
Prime Medicine Secures $144M Funding Boost with Strategic Cystic Fibrosis Foundation Investment - Stock Titan
Prime Medicine stock falls after pricing public offering By Investing.com - Investing.com Australia
Press Release: Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - 富途牛牛
JonesTrading Maintains a Buy on Prime Medicine (PRME) - Insider Monkey
Cathie Wood’s ARK buys Prime Medicine, sells CRISPR stock By Investing.com - Investing.com South Africa
Cathie Wood’s ARK buys Prime Medicine, sells CRISPR stock - Investing.com
Prime Medicine Announces $120.2M Public Stock Offering - TipRanks
Is it the right time to buy Prime Medicine Inc. stockBest Dividend Insights For Fast Growth - Jammu Links News
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
Prime Medicine stock falls after pricing public offering - Investing.com
Why Did Prime Medicine Plunge 13.01%? Regulatory Setbacks, Partnership Concerns - AInvest
Prime Medicine drops on $125 mln equity raise - TradingView
Key resistance and support levels for Prime Medicine Inc.Fast Exit and Entry Strategy Guide Offered - metal.it
Prime Medicine Announces Pricing of Public Offering - GlobeNewswire
Prime Medicine's $125M Fundraise: A Strategic Inflection Point for Gene Editing Innovation - AInvest
0.24%
3.39%
자본화:
|
볼륨(24시간):